Pular para o conteúdo principal
Ranking Invest

CRVS - Corvus Pharmaceuticals, Inc.

Segmento: HealthcareCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Análise Ranking Invest

Valuation estimado
-8,62%
$ 73.08 Mi
Valor de Mercado
$ 1.08 Bi
Sobrepreço (AV)+1383.8%
IVR
0.07A companhia vale 0,07 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.14O valuation alternativo equivale a -14% do valor de mercado da companhia.
MLL
-0.14O lucro líquido dos controladores em 16 trimestres equivale a -14% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 225.33 Mi

Dívida Líquida

-$ 18.91 Mi

L4T

-$ 54.13 Mi

Indicadores Básicos

ROE

-24.02%

Índices de Previsibilidade

Receita Líquida

A0.00

Lucro

D0.63

Margem

A0.00

Índices de Tendência

Receita Líquida

D0.00

Lucro

D-0.35

Margem

D0.00

Índices de Endividamento

DIV/PAT

-0.08

DIV/L4T

0.35

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.